China Blood Product Industry Report, 2020-2026
  • Jan.2020
  • Hard Copy
  • USD $3,400
  • Pages:160
  • Single User License
    (PDF Unprintable)       
  • USD $3,200
  • Code: ZLC096
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $4,800
  • Hard Copy + Single User License
  • USD $3,600

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimbursement from the national medical insurance system. In 2019, the lot release of blood products in China increased further and reached 89.89 million bottles with a year-on-year surge of 21.6%.

Elaborately, the lot release of human albumin rose 17.2% on an annualized basis, making up 58.9%; that of human rabies immunoglobulin soared by 42.9% and accounted for 13.6%; that of human immunoglobulin (pH4) for intravenous injection as a percentage of 13% in the total showed a year-on-year increase of 14.1%; and that of human tetanus immunoglobulin surged by 76.7% and occupied 6.9%.

Other products had small shares, such as human fibrinogen, three kinds of special immunoglobulin, human prothrombin complex, human coagulation factor Ⅷ, particularly coagulation factor category as the lifesaving drug to the victims of hemophilia are often in short supply largely because of the shortage of plasma raw materials domestically as well as the low utilization of plasma.

As the prices of blood products are decontrolled and new plasma stations accelerate to be constructed in recent years, plasma collection in China has been growing year after year, reaching 8,600 tons or more in 2018 with a year-on-year increase of 7.5%. Of all, Beijing Tiantan Biological Products Co., Ltd in possession of 57 plasma stations ranked first by plasma collection up to 1,568.7 tons, a 16.5% share of the total, and its production efficiency gets improved significantly after an asset restructuring.

blood products_副本.png

There are now about thirty blood product enterprises in China, but they are small-sized without rich product portfolios. The industry desires to be concentrated. It is starting from 2008 that the leading players staged mergers and acquisitions and have been developing apace mainly through M&A whilst independently building plasma stations. Meanwhile, some influential companies have turned their attention to overseas resources and good mode and have been actively exploring overseas markets through acquisitions and introducing state-of-the-art technologies from abroad. Undoubtedly, the Chinese market of blood products will get ever concentrated.

What’s more, leading competitors beef up research and development of new products successively and strive to improve comprehensive utilization of plasma. A case in point is the coagulation factorⅧ. Only a few Chinese companies such as China Biologic Products Holdings, Inc., Hualan Biological Engineering Co., Ltd., Shanghai RAAS Blood Products Co., Ltd and Green Cross China are competent to produce the coagulation factorⅧ, but the peers including Jiangxi Boya Bio-Pharmaceutical Co., Ltd., Beijing Tiantan Biological Products Co., Ltd., Southern Shuanglin Bio-Pharmacy Co., Ltd. (formerly known as Zhenxing Biopharmaceutical & Chemical Co., Ltd.), Wuhan ZhongyuanRuide Biological Products Co., Ltd., Beijing Bohui Innovation Technology Co., Ltd., Shenzhen Weiguang Biological Products Co., Ltd and Nanyue Biopharming Co., Ltd. are chasing hard and sparing no efforts in the development of the coagulation factorⅧ. 

China Blood Product Industry Report, 2020-2026 covers the following:
20120114.gifBlood product market (policy, status quo, market structure, supply & demand, market size and competitive pattern);
20120114.gifBlood product market segments (development, bidding price, competitive landscape);
20120114.gif13 blood product companies (operation, revenue structure, gross margin and blood product business, etc.);
20120114.gifSummary and forecast.

1. Blood Products
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features

2. China Blood Product Market
2.1 Policies
2.2 Status Quo
2.3 Market Structure
2.4 Market Supply and Demand
2.4.1 Supply
2.4.2 Demand
2.5 Market Size
2.6 Competition Pattern

3. China Blood Product Market Segments
3.1 Human Albumin
3.1.1 Development Status
3.1.2 Bid Price
3.1.3 Market Structure
3.1.4 Competition Pattern
3.1.5 Prospects
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
3.2.1 Development Status
3.2.2 Bid Price
3.2.3 Competition Pattern
3.2.4 Prospects
3.3 Coagulation Factor VIII
3.3.1 Development Status
3.3.2 Bid Price
3.3.3 Competition Pattern
3.3.4 Prospects
3.4 Hepatitis B Immunoglobulin
3.4.1 Development Status
3.4.2 Bid Price
3.4.3 Competition Pattern
3.5 Human Immunoglobulin
3.5.1 Development Status
3.5.2 Bid Price
3.5.3 Competition Pattern
3.6 Human Prothrombin Complex
3.6.1 Development Status
3.6.2 Bid Price
3.6.3 Competition Pattern
3.7 Tetanus Immunoglobulin
3.7.1 Development Status
3.7.2 Bid Price
3.7.3 Competition Pattern
3.8 Human Rabies Immunoglobulin
3.8.1 Development Status
3.8.2 Bid Price
3.8.3 Competition Pattern

4. Major Enterprises
4.1 China Biologic Products (CBPO)
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R&D Investment
4.1.6 Blood Products Business
4.1.7 Guizhou Taibang Biological Products Co., Ltd.
4.1.8 Shandong Taibang Biological Products Co., Ltd.
4.1.9 Xi'an Huitian Blood Products Co., Ltd.
4.2 Hualan Biological Engineering Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D Investment
4.2.6 Blood Products Business
4.2.7 Development Strategy
4.3 Shanghai RAAS Blood Products Co., Ltd.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D Investment
4.3.6 Blood Products Business
4.3.7 Development Strategy
4.4 Beijing Tiantan Biological Products
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 R&D Investment
4.4.6 Blood Products Business
4.4.7 Chengdu Rongsheng
4.5 Guangdong Shuanglin Bio-Pharmacy 
4.5.1 Profile
4.5.2 Operation
4.5.3 Gross Margin
4.5.4 R&D Investment
4.5.5 Blood Products Business
4.5.6 Development Strategy
4.6 Jiangxi Boya Bio-Pharmaceutical
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R&D Investment
4.6.6 Blood Products Business
4.6.7 Development Strategy
4.7 Weiguang Biological Products
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 R&D Investment
4.7.6 Blood Products Business
4.7.7 Development Strategy
4.8 Beijing Bohui Innovation Technology
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 R&D Investment
4.8.6 Blood Products Business
4.8.7 Development Strategy
4.9 Wuhan ZhongyuanRuide Biological Products Co., Ltd.
4.9.1 Profile
4.9.2 Operation
4.9.3 Blood Products Business
4.10 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.10.1 Profile
4.10.2 Blood Products Business
4.11 Shanxi Kangbao Biological Product Co., Ltd.
4.11.1 Profile
4.11.2 Blood Products Business
4.12 Green Cross China
4.12.1 Profile
4.12.2 Blood Products Business
4.13 Nanyue Biopharming Corporation Ltd.
4.13.1 Profile
4.13.2 Blood Products Business

5. Summary and Forecast
5.1 Summary
5.2 Development Trend
5.2.1 The Industry Continues to Boom
5.2.2 Industry Integration Speeds Up, Concentration Rises Further
5.2.3 Plasma Collection Volume and Number of Plasma Stations Determine the Status in the Industry
5.2.4 Plasma Volume Increases Progressively
5.2.5 Enterprises Make More Input in R&D of New Products to Sharpen Competitiveness, Comprehensive Utilization of Blood Plasma Gets a Further Rise
5.2.6 Downstream Demand Stimulates the Development of the Industry
5.2.7 Healthcare System Reform Deepens, Gradual Perfection of Medical Insurance System Favors the Development of the Industry
Basic Components of Blood
Plasma Protein Separation Procedure
Classification and Effects of Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products
Comparison of Recombinant Blood Products in China and Overseas
Blood Product Industry Chain
Time Length of Plasma Collection and Separation Process
Comparison between Blood Product Enterprises and Chemical & Pharmaceutical Enterprises in Operating Costs & Expenses
Production & Sales Cycle of Blood Products
Main Policies on China Blood Product Industry, 1986-2018
Development History of China Blood Product Industry
Comparison between China and the United States in Per Capita Consumption of Main Blood Products
Lot Release Volume of Major Blood Products in China, 2014-2019
Blood Product Structure in China (by Lot Release Volume), 2014-2019
Plasma Collection Policies in China vs. USA and European Countries
Per Capita Frequency of Plasma Donation and Plasma Collection Volume in China vs. Euro-America
Number of Plasma Collection Stations and YoY Growth Rate in China, 2008-2019
Plasma Station Approval of Major Blood Product Enterprises in China, 2014-2019
Plasma Collection Volume and YoY Growth Rate in China, 2008-2019
Comparison of Blood Products Listed in National Medical Insurance Catalogue: 2017vs2009
Plasma Supply and Demand in China, 2015-2025E
Comparison of Cap-lift Prices and Original Highest Retail Prices of Blood Products
Market Size of China Blood Product Industry, 2010-2019
Number of Plasma Stations and Plasma Volume of Major Blood Product Enterprises in China, As of Dec. 2019
Main Products of Major Blood Product Manufacturing Enterprises in China
Revenue of Major Blood Product Enterprises in China, 2013-2019
Net Income of Major Blood Product Enterprises in China, 2013-2019
Revenue from Blood Products Business of Major Blood Product Enterprises in China, 2013-2019
Market Share of China Blood Product Industry (by Enterprise), 2018
Market Share of China Blood Product Industry (by Enterprise), 2019
Lot Release Volume and YoY Growth Rate of Human Albumin in China, 2010-2019
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Albumin, 2019
Proportion of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2019
Market Share of Human Albumin in China (by Lot Release Volume), 2018
Market Share of Human Albumin in China (by Lot Release Volume), 2019
Lot Release Volume of Human Immunoglobulin for Intravenous Injection in China, 2010-2019
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Immunoglobulin (pH4) for Intravenous Injection, 2019
Market Share of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2018
Market Share of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2019
Comparison between China and the United States in Per Capita Consumption of Human Albumin and Human Immunoglobulin (pH4) for Intravenous Injection
Lot Release Volume of Blood Coagulation Factor VIII in China, 2010-2019
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Coagulation Factor VIII, 2019
Market Share of Blood Coagulation Factor VIII in China (by Lot Release Volume), 2018
Market Share of Blood Coagulation Factor VIII in China (by Lot Release Volume), 2019
Comparison between China and the United States in Per Capita Consumption of Coagulation Factor VIII
Coagulation Factor VIII R&D Progress of Major Blood Product Enterprises in China, as of 2019H1
Lot Release Volume of Hepatitis B Immunoglobulin in China, 2010-2019
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Hepatitis B Immunoglobulin, 2019 
Market Share of Hepatitis B Immunoglobulin in China (by Lot Release Volume), 2018
Market Share of Hepatitis B Immunoglobulin in China (by Lot Release Volume), 2019
Lot Release Volume of Human Immunoglobulin in China, 2010-2019
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Immunoglobulin, 2019
Market Share of Human Immunoglobulin in China (by Lot Release Volume), 2018
Market Share of Human Immunoglobulin in China (by Lot Release Volume), 2019
Lot Release Volume of Human Prothrombin Complex in China, 2010-2019
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Prothrombin Complex, 2019
Market Share of Human Prothrombin Complex in China (by Lot Release Volume), 2018
Market Share of Human Prothrombin Complex in China (by Lot Release Volume), 2019
Lot Release Volume of Tetanus Immunoglobulin in China, 2010-2019
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Tetanus Immunoglobulin, 2019
Market Share of Tetanus Immunoglobulin in China (by Lot Release Volume), 2018
Market Share of Tetanus Immunoglobulin in China (by Lot Release Volume), 2019
Cases, Deaths and Mortality of Rabies in China, 2013-2019
Lot Release Volume of Human Rabies Immunoglobulin in China, 2010-2019
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Rabies Immunoglobulin, 2019
Market Share of Human Rabies Immunoglobulin in China (by Lot Release Volume), 2018
Market Share of Human Rabies Immunoglobulin in China (by Lot Release Volume), 2019
Product Line of CBPO
Equity Structure of China Biologic Products Holdings
Revenue and Operating Income of CBPO, 2014-2019
Revenue Breakdown of CBPO (by Product), 2012-2019
Revenue Structure of CBPO (by Product), 2012-2019
Gross Margin of CBPO, 2012-2019
R&D Costs and % of Total Revenue of CBPO, 2012-2019
CBPO’s Products under Research and R&D Process by the end of 2018
Main R&D Pipeline Products of Beijing TianXinFu Medical Appliance
Lot Release Volume of Blood Products of CBPO, 2016-2019
Main Plasma Collection Stations of Guizhou Taibang Biological Products as of Dec. 2019
Ownership Structure of Shandong Taibang Biological Products
Main Plasma Collection Stations of Shandong Taibang Biological Products as of Dec. 2019
Ownership Structure of Xi'an Huitian Blood Products
Main Plasma Collection Stations of Xi'an Huitian Blood Products as of Dec.2019
Lot Release Volume of Blood Products of Xi'an Huitian Blood Products, 2017-2019
Revenue and Net Income of Hualan Biological Engineering, 2013-2019
Revenue Breakdown of Hualan Biological Engineering (by Product), 2013-2019
Revenue Structure of Hualan Biological Engineering (by Product), 2013-2019
Gross Margin of Blood Products of Hualan Biological Engineering (by Product), 2013-2019
R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2013-2019
Category and Specification of Blood Products of Hualan Biological Engineering
Output, Sales Volume and Inventory of Blood Products of Hualan Biological Engineering, 2016-2018
Revenue of Blood Products of Hualan Biological Engineering, 2013-2019
Lot Release Volume of Blood Products of Hualan Biological Engineering, 2015-2019
Revenue and Net Income of Shanghai RAAS Blood Products, 2013-2019
Revenue Breakdown of Shanghai RAAS Blood Products (by Product), 2013-2019
Revenue Structure of Shanghai RAAS Blood Products (by Product), 2013-2019
Revenue Breakdown of Shanghai RAAS Blood Products (by Region), 2013-2019
Revenue Structure of Shanghai RAAS Blood Products (by Region), 2013-2019
Gross Margin of Shanghai RAAS Blood Products (by Product), 2013-2019
R&D Costs of Shanghai RAAS Blood Products, 2013-2019
Blood Products of Shanghai RAAS Blood Products and Its Subsidiaries
Output, Sales Volume and Inventory of Blood Products of Shanghai RAAS Blood Products, 2016-2018
Revenue and Net Income of Tiantan Biological Products, 2013-2019
Revenue Breakdown of TIANTANBIO (by Product), 2013-2019
Revenue Structure of TIANTANBIO (by Product), 2013-2019
Gross Margin of TIANTANBIO (by Product), 2013-2018
R&D Costs and % of Total Revenue of TIANTANBIO, 2013-2019
R&D Input of Major Projects of TIANTANBIO, 2018
Progress of Major R&D Projects of TIANTANBIO, by the End of 2018
TIANTANBIO’s Major Blood Products Subsidiaries and Stake
Production and Sales of Main Blood Products of TIANTANBIO, 2018
Lot Release Volume of Main Blood Products of TIANTANBIO, 2015-2019
Revenue and Net Income of Chengdu Rongsheng Pharmaceutical, 2015-2019
Revenue and Net Income of Shuanglin Bio-Pharmacy, 2013-2019
Gross Margin of Shuanglin Bio-Pharmacy, 2013-2019
R&D Costs and % of Total Revenue of Guangdong Shuanglin Bio-Pharmacy, 2013-2019
Production-use Plasma Volume of Guangdong Shuanglin Bio-Pharmacy, 2013-2018
Production, Inventory and Sales of Main Blood Products of Guangdong Shuanglin Bio-Pharmacy, 2013-2018
Lot Release Volume of Blood Products of Guangdong Shuanglin Bio-Pharmacy, 2015-2019
Revenue and Net Income of Jiangxi Boya Bio-Pharmaceutical, 2013-2019
Revenue Breakdown of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2018
Revenue Structure of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2018
Revenue from Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2018
Revenue Proportion of Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2018
Gross Margin of Jiangxi Boya Bio-Pharmaceutical (by Product), 2013-2018
Gross Margin of Main Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2013-2018
R&D Costs of Jiangxi Boya Bio-Pharmaceutical, 2013-2019
Production and Sales of Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2016-2018
Lot Release Volume of Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2019
Revenue and Net Income of Shenzhen Weiguang Biological Products, 2014-2019
Revenue Breakdown of Shenzhen Weiguang Biological Products (by Product), 2014-2019
Revenue Structure of Shenzhen Weiguang Biological Products (by Product), 2014-2019
Gross Margin of Shenzhen Weiguang Biological Products, 2014-2019
Gross Margin of Shenzhen Weiguang Biological Products (by Product), 2014-2019
R&D Costs and % of Total Revenue of Shenzhen Weiguang Biological Products, 2014-2019
Progress of Fundraising Projects of Shenzhen Weiguang Biological Products, as of 2019H1
Plasma Collection Volume of Shenzhen Weiguang Biological Products, 2014-2019
Production and Sales of Blood Products of Shenzhen Weiguang Biological Products, 2016-2018
Financial Data of Plasma Collection Stations of Shenzhen Weiguang Biological Products, 2016-2018
Financial Data of Plasma Collection Stations of Shenzhen Weiguang Biological Products, 2019H1
Lot Release Volume of Blood Products of Shenzhen Weiguang Biological Products, 2016-2019
Revenue and Net Income of Beijing Bohui Innovation Technology, 2014-2019
Revenue Breakdown of Beijing Bohui Innovation Technology by Product, 2014-2019
Revenue Structure of Beijing Bohui Innovation Technology by Product, 2014-2019
Gross Margin of Beijing Bohui Innovation Technology by Product, 2014-2019
R&D Costs and % of Total Revenue of Beijing Bohui Innovation Technology, 2014-2019
Progress of Major Blood Product R&D Projects of Beijing Bohui Innovation Technology, 2019H1
Major Blood Products of Beijing Bohui Innovation Technology
Financials of Beijing Bohui Innovation Technology, 2017-2019
Lot Release Volume of Blood Products of Hebei Da’an Pharmaceutical, 2016-2019
Lot Release Volume of Blood Products of Guangdong Weilun Biological Pharmaceutical, 2016-2019
Development Course of Zhongyuan Ruide Biological Products
Financial Data of Zhongyuan Ruide, 2014-2017
Plasmapheresis Centers of Wuhan ZhongyuanRuide Biological Products, as of Dec.2019
Lot Release Volume of Blood Products of Zhongyuan Ruide Biological Products, 2016-2019
Development History of Sichuan Yuanda Shuyang Pharmaceutical
Specification of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical
Lot Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical, 2016-2018
Plasma Collection Stations of Shanxi Kangbao Biological Product as of Dec. 2019
Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2016-2019
Plasma Collection Stations of Green Cross China as of Jan. 2019
Lot Release Volume of Blood Products of Green Cross China, 2016-2019
Plasmapheresis Centers of Nanyue Biopharming, as of Dec.2019
Lot Release Volume of Blood Products of Nanyue Biopharming, 2016-2018
Market Size of Blood Products in China, 2018-2026E
M&A Cases of Foreign Blood Product Companies
M&A Cases in China Blood Product Industry, 2008-2019
Plasma Collection Volume and YoY Change in China, 2018-2026E
R&D Investment of Major Chinese Blood Product Enterprises, 2014-2019
Population Aged above 60 as a Percentage of Total Population in China, 2009-2018

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号